• Ironwood named Jeffrey Silber chief medical officer, head of research and drug development, succeeding retiring CMO Michael Shetzline.
• Silber starts July 20, 2026; Shetzline will stay on as an advisor during the transition.
• Silber will oversee research and drug development, regulatory affairs, medical affairs, reporting to CEO Tom McCourt.
• He joins from Vedanta Biosciences, where he served as chief medical officer since 2020, leading microbiome-based GI therapy development.
• Earlier roles included senior vice president in clinical development at EMD Serono/Merck KGaA, vice president at AbbVie, leadership posts at Merck.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ironwood Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714515996) on July 14, 2026, and is solely responsible for the information contained therein.